Introduction
Male sexual dysfunction is defined as a clinically significant disturbance in a man’s ability to respond sexually or to experience sexual pleasure.1 Erectile dysfunction (ED) is the most common problem of male sexual dysfunction and considered primarily a problem of men older than 40 years of age.2 Data from the 2015–2016 Nation Health and Wellness Survey provide estimates of the global prevalence of ED in men aged 40–70 years old—overall 45.2%: Italy (52.5%), France (47.8%), China (47.4%), Spain (46.6%), Germany (46.1%), US (46,1%), UK (42.6%) and Brazil (42.1%).3 A meta-analysis estimates that the prevalence of ED in Asia (Japan, Korea, China, Singapore) is 41.5% in men aged 40–49, 61.8% in men aged 50–59 and 69.6% in men aged 60–69.4 In Japan, the reported prevalence of ED among at-risk age groups to be 63.7% in men aged 40–49 years, 78.2% in men aged 50–59 years and 90.3% in men aged 60–69 years.4 ED is a common condition in the primary care setting and negatively affects quality of life (QOL).5 6
Historically, treatment of sexual dysfunction was primarily psychosocial until the development of testosterone replacement in 1970s.7 Unfortunately, testosterone injections and patch formulations both have high rates of side effects, and compliance is difficult,8 particularly with injected testosterone. Moreover, the Food and Drug Administration in the USA considers testosterone to be a controlled substance which poses a significant barrier to access.9 In Japan, only testosterone injection is available, but testosterone replacement therapy is approved only for hypogonadism treatment.10
The advent of phosphodiesterase type 5 (PDE5) inhibitors created a new opportunity for treatment of ED. PDE5 inhibitors work by inhibiting guanosine 3',5'-cyclic monophosphate (cGMP) hydrolysis. The accumulation of cGMP leads to smooth-muscle relaxation in the corpus cavernosum and increased blood flow to the penis. Thus, an increase in cGMP in smooth muscle cells is responsible for prolonging an erection.11 Four types of oral PDE5 inhibitors are available in the USA. In Japan, only sildenafil, vardenafil and tadalafil are available, and these three agents can be prescribed by any physician with a medical license including primary care physicians (PCPs). By extrapolating from the 2001–2002 National Health and Nutrition Examination Survey, it has been estimated that the cost associated with treatment of ED would be US$15 billion in the USA if all men affected with ED were to seek treatment.12 However, global sales of PDE5 inhibitors were US$4.82 billion in 2017,13 suggesting that many men afflicted with ED may be untreated. While not suggesting that all men should be treated for ED, this gap suggests that there may be many men who would benefit from treatment for ED as a component of an overall treatment strategy.
Even though ED occurs commonly and effective treatment is available, many patients do not seek treatment for sexual dysfunction.14–17 Previous international research on barriers to seeking treatment showed many patients were concerned there would be no treatment and doctors would dismiss their complaints.18 Compared with men in western countries, men in East Asia (China, Hong Kong, Taiwan, South Korea and Japan) were the least likely to take any action.14 15 17 In one study, lack of perception of a problem and the belief that sexual dysfunction is not a medical issue were the most frequent reasons cited for not seeking medical help among East Asian men.17 Embarrassment about having a sexual problem has also been found as a main reason in East Asian countries.17 Qualitative research in China showed patients perceived sexual dysfunction as embarrassing and potentially shameful, and that men preferred consultation with same gender and age PCPs.19 A previous study in Korea showed only 2% of people with sexual dysfunction had talked to a medical doctor about their sexual problems due to believing that the problem is not serious, not being bothered by the problem, not having access to medical care and lacking of awareness of available treatments.20 A previous study conducted in Japan with PCPs identified the perception that the act of seeking sexual dysfunction treatment may be intensely embarrassing for Japanese men.21
While many men may perceive that sexual dysfunction falls primarily in the scope of care of urologists, PCPs far outnumber urologists and are positioned to provide PDE5 inhibitor therapy for men desiring ED treatment. Previous research in China suggests patients view PCPs as the most appropriate professional with whom to discuss sexual problems.19 However, Nicolosi et al estimated about 90% of East Asian people with some degree of sexual dysfunction had never talked about the problem with their PCPs.17 As treatment could enhance the QOL of men with ED, PCPs need to better understand patient’s perspectives on sexual dysfunction.
Previous research conducted in East Asia showed lack of perception of sexual problems and belief that sexual dysfunction is not a medical issue as main reasons for not seeking medical help.17 We hypothesised Japanese patients may not recognise their sexual dysfunction as a medical problem. Our secondary aims were to examine factors that would be barriers to consulting for treatment and gain a greater understanding qualitatively of participants’ perspectives on sexual dysfunction. Our mixed methods purpose was to integrate the quantitative and qualitative results by merging attitudinal factors with the qualitative perspectives.
The purposes of this research were (1) to examine at-risk Japanese men’s awareness of ED by comparing a single item self-perception assessment of sexual dysfunction with a five-item objective measure of ED, to assess their desire for treatment, and to gauge attitudes about treatment by PCPs, (2) to qualitatively elucidate participating men’s perspectives about their preferences for sexual dysfunction treatment based on written comments and (3) to merge both types of findings to gain an enhanced understanding of how the men’s awareness of ED, desire for treatment and barriers to access linked with their perspectives about ED using joint display analysis and development of a model.